Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-28
DOI
10.1007/s11523-020-00738-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?An analysis of the WHO’s adverse drug reactions database
- (2020) Thủy Nguyễn et al. ANNALS OF THE RHEUMATIC DISEASES
- An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System
- (2020) Kathryn Marwitz et al. DRUG SAFETY
- Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors – a WHO pharmacovigilance database analysis
- (2020) Melissa Y.Y. Moey et al. EUROPEAN RESPIRATORY JOURNAL
- Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors
- (2020) Shipra Gandhi et al. Immunotherapy
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program
- (2020) Javier Jimenez et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
- (2020) Takumi Onoyama et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
- (2020) Charles Dolladille et al. Journal for ImmunoTherapy of Cancer
- Solid organ transplant rejection associated with immune-checkpoint inhibitors
- (2020) S. Saberianfar et al. ANNALS OF ONCOLOGY
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- Adverse events associated with immune checkpoint inhibitor treatment for cancer
- (2019) Khashayar Esfahani et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system
- (2019) Huaqiang Zhou et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
- (2019) Iosune Baraibar et al. DRUG SAFETY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
- (2019) Emanuel Raschi et al. Targeted Oncology
- Hematologic Complications of Immune Checkpoint Inhibitors
- (2019) Elizabeth J. Davis et al. ONCOLOGIST
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
- (2019) Huan-huan Ji et al. CLINICAL DRUG INVESTIGATION
- Multiple sclerosis outcomes after cancer immunotherapy
- (2019) Catherine R. Garcia et al. Clinical & Translational Oncology
- Adverse events 2.0—Let us get SERIOs
- (2019) Lucie Heinzerling et al. EUROPEAN JOURNAL OF CANCER
- Immune checkpoint inhibitor–associated hypophysitis—World Health Organisation VigiBase report analysis
- (2019) Elisa Guerrero et al. EUROPEAN JOURNAL OF CANCER
- New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
- (2019) Arantzazu Barquín-García et al. European Journal of Internal Medicine
- Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system
- (2019) Pushkar Aggarwal Expert Opinion On Drug Safety
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
- (2019) Irene Cortese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
- (2019) Douglas B. Johnson et al. Journal for ImmunoTherapy of Cancer
- Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports
- (2019) Roberta Noseda et al. Journal for ImmunoTherapy of Cancer
- Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy
- (2019) Irene Tsung et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
- (2019) Emanuel Raschi et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
- (2019) Xiaoying Sun et al. BMC CANCER
- Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication
- (2019) Stephane Ederhy et al. EUROPEAN JOURNAL OF HEART FAILURE
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- (2019) Audrey Simonaggio et al. JAMA Oncology
- Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects
- (2019) Andrea Lombardi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
- (2019) Emanuel Raschi et al. ONCOLOGIST
- Workup and Management of Immune‐Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment
- (2019) Christine Hsu et al. ONCOLOGIST
- Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution
- (2019) Ippazio Cosimo Antonazzo et al. ACTA DIABETOLOGICA
- Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors
- (2019) Ethan D. Miller et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Reduced neuropsychiatric events as “beneficial reactions” to drugs: Seek associations with caution
- (2019) Emanuel Raschi et al. BRAIN BEHAVIOR AND IMMUNITY
- Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database VigiBase
- (2019) Xuefeng Bai et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data
- (2019) Qianqian Fan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Diagnosis and Management of Rare Immune‐Related Adverse Events
- (2019) Sara R. Schoenfeld et al. ONCOLOGIST
- Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
- (2019) Hiroaki Akamatsu et al. ONCOLOGIST
- Novel Immunotherapy Combinations
- (2019) Babar Bashir et al. Current Oncology Reports
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
- (2019) Yinghong Zhai et al. Journal for ImmunoTherapy of Cancer
- Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors
- (2019) Aurore Vozy et al. EUROPEAN JOURNAL OF CANCER
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Checkpoint inhibitor-associated immune arthritis
- (2018) Laurent Arnaud et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune-mediated cholangitis: is it always nivolumab’s fault?
- (2018) Francesco Gelsomino et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
- (2018) Lisa A. Kottschade Current Oncology Reports
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
- (2018) Yasuo Oshima et al. JAMA Oncology
- Immune Checkpoint Inhibitor–Associated Myositis
- (2018) Céline Anquetil et al. CIRCULATION
- Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis
- (2018) Kohei Ogawa et al. HEPATOLOGY
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor Toxicity
- (2018) David J. Palmieri et al. Current Oncology Reports
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab
- (2018) Shoko Noda-Narita et al. EUROPEAN JOURNAL OF CANCER
- Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review
- (2018) Georges E. Tanios et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
- (2017) Yasser M. Alatawi et al. Expert Opinion On Drug Safety
- ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations
- (2017) Emanuel Raschi et al. Internal and Emergency Medicine
- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
- (2017) Hisato Kawakami et al. INVESTIGATIONAL NEW DRUGS
- A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
- (2017) Francesco Gelsomino et al. INVESTIGATIONAL NEW DRUGS
- Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies
- (2017) Ayad K. Ali et al. PHARMACOTHERAPY
- Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
- (2017) Amandine Gouverneur et al. Targeted Oncology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.
- (2016) F. Gelsomino et al. ANNALS OF ONCOLOGY
- Good Signal Detection Practices: Evidence from IMI PROTECT
- (2016) Antoni F. Z. Wisniewski et al. DRUG SAFETY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies
- (2015) Miguel-Angel Maciá-Martínez et al. DRUG SAFETY
- The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project
- (2015) Emanuel Raschi et al. DRUG SAFETY
- Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database
- (2014) Paola M. Cutroneo et al. DRUG SAFETY
- Adverse reactions to oncologic drugs: spontaneous reporting and signal detection
- (2014) Marco Tuccori et al. Expert Review of Clinical Pharmacology
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Challenges of Guarantee-Time Bias
- (2013) Anita Giobbie-Hurder et al. JOURNAL OF CLINICAL ONCOLOGY
- When to publish measures of disproportionality derived from spontaneous reporting databases?
- (2011) Anthonius de Boer BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
- (2011) Jean-Louis Montastruc et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Mapping the Safety Profile of Biologicals
- (2010) Thijs J. Giezen et al. DRUG SAFETY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started